Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.53−0.08 (-4.97%)
Close on Nov 18, 2026Market cap $3.59MP/E –Yield –
Xenetic Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Xenetic Biosciences's revenue for the twelve months ending Jun 30, 2026 was $3.26M, up 33.3% year over year. For fiscal 2025 it was $2.98M, up 19.0% from the year before. The highest annual figure on record is $7.59M in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.98M | +19.0% |
| FY2024 | Dec 31, 2024 | $2.50M | -1.6% |
| FY2023 | Dec 31, 2023 | $2.54M | +48.8% |
| FY2022 | Dec 31, 2022 | $1.71M | +47.1% |
| FY2021 | Dec 31, 2021 | $1.16M | +165.6% |
| FY2020 | Dec 31, 2020 | $436.94K | +2460.3% |
| FY2019 | Dec 31, 2019 | $17.07K | – |
| FY2018 | Dec 31, 2018 | $0 | -100.0% |
| FY2017 | Dec 31, 2017 | $7.59M | +152.8% |
| FY2016 | Dec 31, 2016 | $3.00M | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $1.00M | +240.6% |
| FY2012 | Dec 31, 2012 | $293.60K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $660.60K | +12.0% |
| Q1 FY2026 | Mar 31, 2026 | $806.92K | +36.0% |
| Q4 FY2025 | Dec 31, 2025 | $766.30K | +18.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.03M | +67.2% |
| Q2 FY2025 | Jun 30, 2025 | $589.90K | -18.8% |
| Q1 FY2025 | Mar 31, 2025 | $593.26K | +16.1% |
| Q4 FY2024 | Dec 31, 2024 | $648.82K | -3.4% |
| Q3 FY2024 | Sep 30, 2024 | $614.24K | +0.5% |
| Q2 FY2024 | Jun 30, 2024 | $726.40K | +11.6% |
| Q1 FY2024 | Mar 31, 2024 | $510.82K | -15.7% |
| Q4 FY2023 | Dec 31, 2023 | $671.96K | +61.3% |
| Q3 FY2023 | Sep 30, 2023 | $611.17K | +57.1% |
| Q2 FY2023 | Jun 30, 2023 | $651.01K | +95.7% |
| Q1 FY2023 | Mar 31, 2023 | $605.84K | +73.5% |
| Q2 FY2022 | Jun 30, 2022 | $416.71K | +44.9% |
| Q1 FY2022 | Mar 31, 2022 | $388.99K | +103.4% |
| Q4 FY2021 | Dec 31, 2021 | $332.60K | +119.8% |
| Q3 FY2021 | Sep 30, 2021 | $349.27K | +201.3% |
| Q2 FY2021 | Jun 30, 2021 | $287.60K | +154.7% |
| Q1 FY2021 | Mar 31, 2021 | $191.22K | +237.0% |
| Q4 FY2020 | Dec 31, 2020 | $151.33K | +786.7% |
| Q3 FY2020 | Sep 30, 2020 | $115.93K | – |
| Q2 FY2020 | Jun 30, 2020 | $112.93K | – |
| Q1 FY2020 | Mar 31, 2020 | $56.75K | – |
| Q4 FY2019 | Dec 31, 2019 | $17.07K | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $7.50M | – |
| Q3 FY2017 | Sep 30, 2017 | $85.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $3.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?